Position in INSM
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$179,370,451
+$155,085,279 QoQ
Shares Held
1,682,334
+1032.8% QoQ
Ownership
0.770%
of shares outstanding
% of Portfolio
0.21%
of 13F equity value
Holder Rank
#24
of 652 holders
Holding Since
Sep 2022
9 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in INSM Over Time
Shares Held
Position Value (USD)
Derivatives in INSM
reported options exposure · as of Mar 31, 2024CallValue
$908,855
CallShares
33,500
PutValue
$0
PutShares
0
Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.
Position in Biotechnology
Healthcare · as of Jun 30, 2026Qube Research & Technologies Ltd holds $2,443,018,528 across 169 Biotechnology names. INSM ranks #2 (7.3% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
798,715 | $240,437,176 | |
| 2 | INSM |
INSMED Inc
This page
|
1,682,334 | $179,370,451 | |
| 3 | REGN |
Regeneron Pharmaceuticals, Inc.
|
221,607 | $138,180,828 | |
| 4 | ROIV |
Roivant Sciences Ltd.
|
3,454,496 | $122,254,613 | |
| 5 | AXSM |
Axsome Therapeutics, Inc.
|
426,336 | $104,354,262 | |
| 6 | APGE |
Apogee Therapeutics, Inc.
|
659,678 | $87,559,060 | |
| 7 | TVTX |
Travere Therapeutics, Inc.
|
1,443,230 | $81,989,896 | |
| 8 | RPRX |
Royalty Pharma plc
|
1,412,112 | $79,177,119 |
All Filings in INSM
Export CSV
10 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $179,370,451 | 1,682,334 | Shares | Sole | 2026-08-14 | |
| 2026-03-31 | $24,285,172 | 148,515 | Shares | Sole | 2026-05-15 | |
| 2025-09-30 | $222,396,803 | 1,544,315 | Shares | Sole | 2025-11-14 | |
| 2025-06-30 | $108,897,512 | 1,082,050 | Shares | Sole | 2025-08-14 | |
| 2024-12-31 | $26,858,838 | 389,033 | Shares | Sole | 2025-02-14 | |
| 2024-09-30 | $35,719,411 | 489,307 | Shares | Sole | 2024-11-14 | |
| 2024-03-31 | $4,161,795 | 153,402 | Shares | Sole | 2024-05-14 | |
| 2024-03-31 | $908,855 | 33,500 | Call | Sole | 2024-05-14 | |
| 2023-12-31 | $632,103 | 20,397 | Shares | Sole | 2024-02-13 | |
| 2022-09-30 | $2,619,199 | 121,597 | Shares | Sole | 2022-11-14 | |
| No filing history on record for this holder in this stock. | ||||||